Search results
Results from the WOW.Com Content Network
Ketamine-assisted psychotherapy (KAP) is the use of prescribed doses of ketamine as an adjunct to psychotherapy sessions. KAP shows significant potential in treating mental disorders such as treatment-resistant depression (TRD), anxiety , obsessive–compulsive disorders (OCD), post-traumatic stress disorders (PTSD), and other conditions. [ 1 ]
Evidence is growing for the use of atypical psychedelics such as ketamine for treating depression in terminally ill patients, with repeated IV administration having the most therapeutic effect. [62] These studies did not have any patients experience any serious adverse effects; however, ketamine-induced ulcerative cystitis is a concern for ...
Ketamine is used as a recreational drug for its hallucinogenic and dissociative effects. [24] When used recreationally, it is found both in crystalline powder and liquid form, and is often referred to by users as "Special K" or simply "K". The long-term effects of repeated use are largely unknown and are an area of active investigation.
At the Boise Ketamine Clinic, the cost of ketamine is $350 per session in lozenge form, which is self-guided with monitoring from a nurse for 40 minutes to an hour, and $600 per session for ...
How ketamine therapy is different from recreational use. Ketamine has long been studied for its potential mental health benefits as well, specifically in managing treatment-resistant depression ...
Here, we explore ketamine therapy’s safety with Steven L. Mandel, M.D., co-founder of Ketamine Clinics Los Angeles and the founder of the nonprofit American Society of Ketamine Physicians ...
Reid Robison (born September 1976 in Illinois) is an American board-certified psychiatrist known primarily for his work with psychedelic medicines.As an early adopter and researcher of the use of ketamine in psychiatry, Robison has made significant contributions to ketamine-assisted psychotherapy (KAP) and other treatment modalities using ketamine for mental health conditions.
In October 2023, the FDA warned about using the substance to treat psychiatric disorders in non-injectable forms, noting that safety concerns that may be associated with ketamine usage include ...